NCM · Biotechnology

Indaptus Therapeutics, Inc. (INDP) Stock

$2.51 +5.91% NCM: INDP Healthcare

Valuation

MetricValue
Price$2.51
Market Cap$284.24M
P/E Ratio-0.34
P/B Ratio24.30
P/S Ratio0.00
EPS (TTM)$-21.58
52-Week High$5.96
52-Week Low$0.92
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-302.75%
ROA-128.66%
ROCE-129.90%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio1.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-8.0M$-15.0M$-16.0M$-15.0M$-20.0M
Net Profit$-8.0M$-14.0M$-15.0M$-15.0M$-21.0M
EPS$-52.78$-48.54$-51.41$-44.96$-21.58
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$41.0M$28.0M$15.0M$7.0M$9.0M
Total Liabilities$5.0M$3.0M$3.0M$3.0M$6.0M
Cash$39.0M$10.0M$13.0M$6.0M$9.0M
Borrowings$0$0$0$0$0

Latest News

Top Premarket Decliners MT Newswires · Jun 5, 2026 Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-13.0M$-13.0M$-12.0M$-15.0M
Investing Cash Flow$0$-17.0M$17.0M$0$0
Financing Cash Flow$43.0M$0$0$-1.0M$0
Net Cash Flow$37.0M$-30.0M$4.0M$-8.0M$3.0M
Free Cash Flow$-11.0M$-13.0M$-13.0M$-12.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-16.95
FCF Yield-5.63%
Quick Ratio19.48
Interest Coverage0.00
Return 1Y-76.87%
Return 3Y-94.70%
Return 5Y-99.25%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. is led by CEO Junyi Dai, employs 7 people, headquartered in US, publicly traded since 2015.

Indaptus Therapeutics, Inc. (INDP) stock trades at $2.51 with a market capitalization of $284.24M. The stock is valued at a price-to-earnings (P/E) ratio of -0.34, price-to-book of 24.30, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.92 and $5.96, and currently trades 57.9% below its 52-week high.

On profitability, Indaptus Therapeutics, Inc. generates a return on equity (ROE) of -302.75%, return on capital employed of -129.90%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides